ACR Convergence 2020

November 5-9, 2020. All Virtual.

View by Number View by Title View Sessions

View by Date

Abstract Number: 0369

Effect of Upadacitinib on Reducing Pain in Patients with Active Ankylosing Spondylitis and Inadequate Response to Nonsteroidal Anti-inflammatory Drugs
Abstract Number: 0370

Guselkumab-Treated Patients Achieved Clinically Meaningful Improvement in Systemic Symptoms as Measured with PROMIS Instrument: Results from Phase-3 Psoriatic Arthritis Trial DISCOVER 1
Abstract Number: 0371

Identifying Inadequate Response Among Ankylosing Spondylitis Patients Prescribed Biologics in a Real-world Commercially Insured Adult Population in the United States
Abstract Number: 0372

Tumor Necrosis Factor-α Receptor 2 Polymorphisms and Response to TNF Inhibitor Therapy in Patients with Psoriatic Arthritis
Abstract Number: 0373

Medical Cannabis in Ankylosing Spondylitis Following Recreational Legalization: A Prospective Cross-sectional Study
Abstract Number: 0374

Neo-epitopes of Type I Collagen Can Be Utilized as Translational Biomarkers for Skin and Joint Turnover in Patients with Psoriasis and Psoriatic Arthritis
Abstract Number: 0375

Efficacy of Disease Modifying Anti-Rheumatic Drugs for Enthesitis in a Prospective Longitudinal Psoriatic Arthritis Cohort
Abstract Number: 0376

Higher Intake of Carbohydrates and Free Sugar Are Associated with Higher Disease Activity in Patients with Axial Spondyloarthritis
Abstract Number: 0377

Evaluation of Sex Differences in the Efficacy and Safety of Tofacitinib in Patients with Active Psoriatic Arthritis: A Post Hoc Analysis of Two Phase 3 Randomized Controlled Trials
Abstract Number: 0378

Itch as the Major Mediator of the Effect of Tofacitinib on Health-Related Quality of Life in Psoriatic Arthritis: A Mediation Analysis
Abstract Number: 0379

Achievement of RAPID3 and cDAPSA Treatment Targets Is Associated with Control of Articular and Extra-Articular Manifestations of Active Psoriatic Arthritis in DMARD-Naive Patients Treated with Apremilast
Abstract Number: 0380

Efficacy and Safety of Ixekizumab in Patients with Psoriatic Arthritis and Inadequate Response to TNF Inhibitors: 3 Year Results from a Phase 3 Study
Abstract Number: 0381

Efficacy of Tofacitinib on Dactylitis in Individual Digits in Patients with Active Psoriatic Arthritis
Abstract Number: 0382

Increased Rates of Obstetric Complications Prior to Systemic Sclerosis Diagnosis
Abstract Number: 0383

Sex Differences in Severity and Progression of Interstitial Lung Disease in Systemic Sclerosis: What We Have Learned from Clinical Trials

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].